Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStomach discomfort on Mounjaro is common, but the biggest misconception is that any belly ache means something is wrong. Most abdominal symptoms — cramping, bloating, a dull ache after eating — are the digestive system adjusting to tirzepatide's effect on gastric emptying, and they tend to ease within days to a couple of weeks. That said, not every belly ache on Mounjaro deserves the same response. As a prescription-only medicine, Mounjaro is dispensed following a clinical assessment, and your prescriber is the right person to advise if symptoms feel severe or persistent.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the worry that brings a lot of people to search engines at 11pm. The reality is more straightforward. Tirzepatide is a dual GIP and GLP-1 receptor agonist, it works partly by slowing the rate at which food leaves the stomach. That mechanism is also what causes the familiar cramping, bloating, and general abdominal grumbling that many people notice in their first few weeks. The gut is doing something different to what it's used to, and it lets you know.
According to the NHS medicines page for tirzepatide, gastrointestinal symptoms (including stomach pain, nausea and diarrhoea) are among the most commonly reported effects. They tend to be most noticeable in the early weeks or after a dose increase, then settle as the body adapts. For most people, the belly ache is a sign the medicine is doing its job, not a sign something has gone wrong.
Eating smaller portions, slowing down at mealtimes, and avoiding very fatty or very rich foods can all reduce the intensity. One practical check: if your symptoms flare badly every time you eat a large or greasy meal, that pattern is almost always dietary rather than a sign of a deeper problem. Worth noting if you're keeping track.
Here is where the nuance matters. Belly ache on Mounjaro is not always a simple adjustment symptom. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 receptor agonist medicines, flagging acute pancreatitis as an infrequent but potentially serious risk. The distinguishing feature is the character of the pain: severe, persistent abdominal discomfort that may spread toward the back, sometimes with vomiting, and does not ease in the normal way.
This is different from the dull, gassy ache that follows a big meal in week two of treatment. Pancreatitis-type pain tends to be intense and continuous rather than crampy and intermittent. If that description fits what you are experiencing, stop reading and get medical help straight away. Call 111, contact your GP, or go to A&E depending on severity. Do not wait to see if it settles overnight.
Other signals that move belly ache out of the "normal adjustment" category: pain accompanied by fever, jaundice (yellowing of the skin or whites of the eyes), or signs of dehydration from repeated vomiting. These all warrant prompt clinical assessment rather than a wait-and-see approach. If you're unsure whether something qualifies as urgent, 111 exists precisely for that call.
People starting tirzepatide sometimes notice that stomach symptoms arrive alongside other physical changes, fatigue, headache, or a general feeling of being off. These are usually connected to reduced food intake and the body recalibrating its energy balance, rather than anything anatomically separate happening. The belly ache is typically the loudest signal in the first few weeks simply because the digestive system is the most directly affected.
Some people also report musculoskeletal discomfort when starting weight-loss treatment, a different kind of ache that has nothing to do with the stomach. If you're curious about that distinction, our page on whether Mounjaro causes general aching covers it in more detail. Back pain specifically is explored separately on our Mounjaro back ache page, and if you've noticed discomfort around the hips rather than the stomach, our page on Mounjaro hip pain looks at why that can happen and what to do about it.
The belly ache question also gets tangled with questions about fat loss, people wonder whether abdominal discomfort is connected to changes in belly fat. It isn't directly, but if that's something you're thinking about, our piece on Mounjaro and belly fat separates the clinical evidence from the common assumptions. The full picture of how tirzepatide works is on our tirzepatide overview.
If symptoms are mild and improving week on week, you probably don't need to do anything urgently beyond the dietary adjustments above. If they are not improving after two to three weeks at a given dose, or if they are significant enough to affect daily life, that is a conversation worth having with whoever manages your prescription. There may be practical strategies (timing of the injection, meal composition, hydration) that help, or the prescriber may want to consider whether the titration schedule needs adjusting.
At nume, our prescribers are available seven days a week for aftercare questions, and no repeat order goes out without a fresh clinical review. If you're thinking about starting treatment and want to understand whether Mounjaro is clinically suitable for you, the right starting point is a free consultation, details are on our weight-loss treatments page. You can also read about how the full Mounjaro prescribing process works on our Mounjaro information page.
Suspected side effects, including any that concern you, can be reported directly to the MHRA via the Yellow Card scheme. Reporting helps build the post-market safety record for newer medicines like tirzepatide.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.